The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Patients treated with clopidogrel who have higher body size exhibit greater platelet reactivity than patients with lower body size. In a retrospective analysis of the FEATHER trial, we examined the relationship between platelet response to thienopyridines clopidogrel 75mg (Clop-75), prasugrel 5mg (Pras-5), and prasugrel 10mg (Pras-10) using 3 body size indices: body weight (BW), body mass index (BMI), and body surface area (BSA). Relationships were assessed as continuous variables and as 4 incremental body size groups.


  • Joseph A Jakubowski
  • Dominick J Angiolillo
  • Chunmei Zhou
  • David S Small
  • Brian A Moser
  • Jurrien M Ten Berg
  • Patricia B Brown
  • Stefan James
  • Kenneth J Winters
  • David Erlinge
Enheter & grupper

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Kardiologi
Sidor (från-till)552-557
TidskriftThrombosis Research
Utgåva nummer3
StatusPublished - 2014
Peer review utfördJa